7.83
0.59 (8.15%)
0.59 (8.15%)
Upgrade to Real-Time
Afterhours (Closed)
| Volume | 826,628 |
|
|||||
| News | - | ||||||
| Day High | 7.87 | Low High |
|||||
| Day Low | 7.12 | ||||||
Best deals to access real time data! |
|
Ultimate Trader (Monthly)
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
Big Cap Pro
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Coherus BioSciences Inc | CHRS | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
 |
|
|---|---|---|---|---|
| 0.59 | 8.15% | 7.83 | 20:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 7.21 | 7.12 | 7.87 | 7.83 | 7.24 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 7,130 | 826,628 | $ 7.58 | $ 6,265,872 | - | 5.60 - 19.32 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 16:05:31 | average | 300 | $ 7.83 | USD |
Period:
Draw Mode:
Coherus BioSciences Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 606.22M | 77.42M | 61.14M | $ 326.55M | $ -230.61M | -3.85 | -2.70 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | - | 177.99k | 1.60% |
Coherus BioSciences News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CHRS Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 7.48 | 7.87 | 7.10 | 7.45 | 896,231 | 0.35 | 4.68% |
| 1 Month | 7.44 | 7.93 | 5.60 | 6.85 | 1,113,138 | 0.39 | 5.24% |
| 3 Months | 12.51 | 12.93 | 5.60 | 8.14 | 1,070,677 | -4.68 | -37.41% |
| 6 Months | 16.09 | 16.48 | 5.60 | 10.38 | 966,861 | -8.26 | -51.34% |
| 1 Year | 13.77 | 19.32 | 5.60 | 12.74 | 805,094 | -5.94 | -43.14% |
| 3 Years | 22.31 | 23.91 | 5.60 | 16.41 | 1,023,051 | -14.48 | -64.9% |
| 5 Years | 14.45 | 23.91 | 5.60 | 15.64 | 890,941 | -6.62 | -45.81% |
Coherus BioSciences Description
| Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an innovative immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. Toripalimab is being evaluated in pivotal clinical trials for the treatment of cancers of the lung, breast, liver, skin, kidney, stomach, esophagus, and bladder. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company is also developing CHS-305, a biosimilar of Avastin. The company generates revenue primarily from the United States. |